Lv11
65 积分 2021-04-12 加入
Factors responsible for noncompliance to drug therapy in the elderly and the impact of patient education on improving compliance
2小时前
已关闭
Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy
10天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
21天前
已完结
Emerging Strategies for the Treatment of Small Cell Lung Cancer
24天前
已完结
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
24天前
已完结
Late Recurrence of Completely Resected Stage I-IIIA Lung Adenocarcinoma
24天前
已完结
Recurrence After Complete Resection for Non-Small Cell Lung Cancer in the National Lung Screening Trial
24天前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
1个月前
已关闭
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
1个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
